Ophthalmology

MSD to Acquire EyeBio for up to $3 Billion

US drugmaker Merck & Co. (MSD) has agreed to acquire privately held ophthalmology-focused biotechnology company Eyebiotech (EyeBio).

Sandoz Acquires Ophthalmology Franchise from Coherus

In a move to expand its ophthalmic platform, Sandoz, the former generics and biosimilars arm of Swiss drugmaker Novartis, has completed the acquisition of Coherus BioSciences’ subsidiary Coherus Ophthalmology for $170 million.

Bayer Combines Pharma R&D in one Unit

Novartis Splits Pharmaceutical Division